/
GRI
$1.77-$0.18 (-9.23%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$3.5M
2M shares
52-week range
$1.36 – $80.36
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-371866.09
GRI Bio, Inc. Common Stock
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
www.gribio.com- Employees
- 5
- IPO / List date
- Apr 24, 2023
- HQ
- LA JOLLA, CA
Held by traders on TradeandTell
No one on the platform currently holds GRI.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GRI as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-01-26 | 1-for-28reverse |
| 2025-02-24 | 1-for-17reverse |
| 2024-06-18 | 1-for-13reverse |
| 2024-01-30 | 1-for-7reverse |
Recent trades on TradeandTell
No one on the platform has traded GRI yet.
